Sarah L. Thompson

Sarah L. Thompson

Auto-generated profile, based on publicly available information

Sarah L. Thompson

Yale University, 300 George Street, New Haven, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in Science
Verified
Journal Article
Closed access
VGVishruth Girish
Vishruth Girish
ALAsad A. Lakhani
Asad A. Lakhani
STSarah L. Thompson
Sarah L. Thompson
CSChristine M. Scaduto
Christine M. Scaduto
LBLeanne M. Brown
Leanne M. Brown
JSJason Sheltzer
Jason Sheltzer
Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of MDM4 and suppresses p53 signaling, and we show that TP53 mutations are mutually exclusive with 1q aneuploidy in human cancers. Thus, tumor cells can be dependent on specific aneuploidies, raising the possibility that these “aneuploidy addictions” could be targeted as a therapeutic strategy.

19 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LJLinda Julian
Linda Julian
LCLisa Crozier
Lisa Crozier
DLDevon Lukow
Devon Lukow
ASAditi Swamy
Aditi Swamy
SMSanat Mishra
Sanat Mishra
JSJason Sheltzer
Jason Sheltzer
The cyclin-dependent kinase CDK11 is an understudied kinase that has been the subject of conflicting reports regarding its function in cancer. Here, we combine genetic and pharmacological approaches to demonstrate that CDK11 is a critical regulator of cancer cell survival that is required for RNA splicing and the expression of homologous recombination genes. Inhibition of CDK11 disrupts genome stability, promotes the retention of intronic sequences in mature mRNAs, and induces synthetic lethality with PARP inhibitors. Through integrative analysis of functional genomics datasets, we identify heterozygous deletions of chromosome 1p36 - which encompasses CDK11 and its activating cyclin CCNL2 - as a recurrent and predictive biomarker of sensitivity to CDK11 inhibition. To assess the therapeutic potential of CDK11, we establish a genetically-engineered mouse model that allows us to differentiate between the on-target and off-target effects of CDK11 inhibitors in vivo. Using this platform, we demonstrate that MEL-495R, an orally bioavailable CDK11 inhibitor, induces widespread on-target toxicity, revealing a narrow therapeutic index. Experiments with a chemically distinct CDK11 inhibitor similarly reveal minimal anti-cancer activity at tolerable doses. Together, these findings define CDK11 as a core cancer dependency, uncover a chromosomal deletion that sensitizes tumors to CDK11 inhibition, demonstrate that on-target toxicity limits the efficacy of CDK11-targeting therapies, and provide a generalizable strategy for deconvolving drug efficacy and toxicity in vivo for novel oncology targets.